Vertigo in childhood. Comments on pathogenesis and management.
D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use; D002490:Central Nervous System / Q000503:physiopathology; D002648:Child; D004111:Dimenhydrinate / Q000627:therapeutic use; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008581:Meningitis / Q000150:complications; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D012640:Seizures / Q000150:complications; D012852:Sinusitis / Q000150:complications; D014717:Vertigo / Q000188:drug therapy / Q000209:etiology*; D014725:Vestibular Nerve / Q000503:physiopathology; D014722:Vestibule, Labyrinth / Q000503:physiopathology; D014947:Wounds and Injuries / Q000150:complications
D000927:Anticonvulsants; D006634:Histamine H1 Antagonists; D010672:Phenytoin; D004111:Dimenhydrinate; D010634:Phenobarbital